ACM Research (Shanghai) reported 65% year-over-year growth in newly signed orders during Q1 2026, with management highlighting progress in high-temperature single-wafer plasma source ion implantation tools achieving 15nm particle control. The company maintained its 2026 revenue guidance unchanged, citing typical 6-month delivery cycles and customer acceptance requirements.